Selecta Biosciences (NASDAQ:SELB) Issues Earnings Results, Beats Expectations By $0.09 EPS

Selecta Biosciences (NASDAQ:SELBGet Rating) announced its quarterly earnings results on Thursday. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.09, Fidelity Earnings reports. Selecta Biosciences had a net margin of 24.85% and a return on equity of 21.22%. During the same quarter in the prior year, the firm earned ($0.04) EPS.

Selecta Biosciences Price Performance

Shares of NASDAQ SELB opened at $2.36 on Friday. The firm has a 50-day simple moving average of $1.39 and a 200-day simple moving average of $1.44. The stock has a market capitalization of $358.27 million, a price-to-earnings ratio of 236.00 and a beta of 1.04. The company has a quick ratio of 3.31, a current ratio of 3.31 and a debt-to-equity ratio of 0.45. Selecta Biosciences has a 52 week low of $0.65 and a 52 week high of $4.70.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on SELB. SVB Leerink initiated coverage on shares of Selecta Biosciences in a report on Monday, June 6th. They set an “outperform” rating and a $7.00 price target on the stock. StockNews.com downgraded shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, May 14th. TheStreet raised shares of Selecta Biosciences from a “d” rating to a “c-” rating in a report on Wednesday, May 25th. HC Wainwright decreased their price objective on shares of Selecta Biosciences from $6.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, June 21st. Finally, Needham & Company LLC decreased their price objective on shares of Selecta Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Tuesday, June 14th. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.33.

Insider Activity

In other Selecta Biosciences news, Director Timothy C. Barabe bought 50,000 shares of Selecta Biosciences stock in a transaction dated Monday, May 9th. The stock was acquired at an average cost of $0.77 per share, for a total transaction of $38,500.00. Following the completion of the transaction, the director now directly owns 250,013 shares of the company’s stock, valued at $192,510.01. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, Director Timothy C. Barabe acquired 50,000 shares of the business’s stock in a transaction that occurred on Monday, May 9th. The stock was purchased at an average cost of $0.77 per share, for a total transaction of $38,500.00. Following the completion of the transaction, the director now owns 250,013 shares in the company, valued at $192,510.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carrie Smith Cox acquired 130,000 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The shares were purchased at an average price of $1.15 per share, with a total value of $149,500.00. Following the completion of the transaction, the director now owns 212,881 shares of the company’s stock, valued at approximately $244,813.15. The disclosure for this purchase can be found here. Company insiders own 30.50% of the company’s stock.

Institutional Investors Weigh In On Selecta Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Mirabella Financial Services LLP acquired a new stake in Selecta Biosciences during the first quarter worth about $82,000. Beacon Pointe Advisors LLC acquired a new stake in shares of Selecta Biosciences during the first quarter valued at about $33,000. Eqis Capital Management Inc. acquired a new stake in shares of Selecta Biosciences during the first quarter valued at about $30,000. State Street Corp increased its position in shares of Selecta Biosciences by 4.7% during the first quarter. State Street Corp now owns 1,790,985 shares of the company’s stock valued at $2,203,000 after acquiring an additional 80,662 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Selecta Biosciences by 213.0% during the first quarter. Renaissance Technologies LLC now owns 1,490,400 shares of the company’s stock valued at $1,833,000 after acquiring an additional 1,014,200 shares during the last quarter. 72.62% of the stock is currently owned by institutional investors and hedge funds.

Selecta Biosciences Company Profile

(Get Rating)

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia.

Further Reading

Earnings History for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.